lymphoma sharing

One case of lymphoma is shared among older males with case information, who pass on to the patient’s platinum health, deny the history of hepatitis, have no history of tuberculosis, deny the history of malaria, deny the history of close contact, have years of hypertensive disease, take oral depressants and control of blood pressure. Denying a history of heart disease, diabetes more than a year old, oral diarrhea, and blood sugar control. Denial of the history of cerebrovascular disease, mental illness, denial of the history of surgery, no history of trauma, no history of blood transfusion, no history of drugs, allergies of food, no history of vaccination. For the first time, 2022-06-16 was admitted to my section due to “abdominal discomfort after January”. 1. Current medical history: In case of abdominal discomfort, no heat, no sweat, visits to provincial hospitals, check B Super: multiple lymph nodes after abdominal cavity and peritoneum, lymphoma? Patients consider that lymphoma could be large and get paid for further treatment. Since the onset of the disease, the patient has had a normal state of mind, diet and sleep and has lost 5 kg of weight for almost a year. 2. Medical examination: T: 36.3°C, P: 74 minutes, R: 18 minutes, BP: 116/72 mmHg. The spirit is clear, the skin mucus is not bleeding, the neck and armpit lymph is swollen, the chest is unpressured, the heart and lungs are not abnormal, the abdominal is soft, the liver is small and the underside is not edema. 3.2022-06-16 haemoglobin [netless red]: haemoglobin 141.00g/L, white cell count 6.07*109/L, blood plate count 329.00*109/L (house, number unknown)Upgrading relevant examinations after admission, 2022-06-16 blood routine [netless red]: haemoglobin 141.00g/L, white cell count 6.07*109/L, blood plate count 329.00*109/L, 2022-06-16 spectrophosphate test: 2022-06-16 hepatitis: sodium 136.8mmol/L, 2022-06-16 [in electric swimming]: gland demasterase 22U/L, emulsicase 572.6U/L, 2022-06-16 nephrenics: urea acid 433.5umol/L, remediate C1q 14590mg/L, 2022-06-16 haemophilosophosphate test: 2022-06-16 blood glucose (air): glucose 6.28mmol/L, 2022-06-16 blood lipid analysis: high-denity galcinol 0.77 mmol/L, low-den-den glycerinol (374 mm/L), 2022-16 haematophophosphate: normal detection of blood. 2022-06-17 PET/CT full body examination concluded: 1.1 increased lymphorate nodes in the left mumps, increased metabolism, SUVx approximately 11.3; 2 left neck area III-V, increased lymphoma nodes over the left collarbone, increased metabolic increase, SUVmax approximately 10.4; 3 double lymphoph nodes increased lymphoma nodes, increased metabolic increase, SUV maxis approximately 8.9; 4-perimeter insulated upper left cavity, several mildly increased lymphoma nodes on the left side of the chest 7 vertebrate, increased metabolism, SUVmax approximately 6.2; lymphoma (heavy and cross-sectional lymphoma, spleen, spleen, spleen, sepsis, sepsis, sepsis, sepmax, suvmax, sept, sepmax, sepsis, sepsis, sepsis, sepsis, dowell rating: 5 points, based on PET/CT results: IIIS) 2. lymphomy, sepsis, high metabolism, consideration of the potential for lymphoma in the lungs, recommended for follow-on observation; chromic inoculation; right-hand lymbrane calcification; coronal calcification of 3. light lymphate; chronic cystitis; left-back muscle fatoma; right-side dysenteral dysenteral cystosis 4-and-half centre, radiary chorus chorus chordium 5. 1 vertic concuss; and retrovertic reversion. At 2022.6.21, bone marrow piercing, bone marrow smears, immunological speculations are not significantly abnormal, 2022-06-28 tissue pathological examination and diagnosis (the lymphoma lymphoma) is considered malignant, pro-lymphoma is possible, plus immunisation results: CD3-), CD20(+), CD10(-), Bcl-2 (+ 70 per cent), Bcl-6 (+ 50 per cent), MUM1(+), c-Myc(+ 40 per cent), CyclinD1(-), CD21 (remaining FDC network +), CD30(-), CD5(-), p53(-), Ki-67(+, approximately 60 per cent), EBER(original) (-), ALK(5A4) (-), CD19(+), Pax-5(+). Combined with the results of immunisation, it is a B-cell lymphoma, with the opinion that the lymphoma of the extended B-cell lymphoma is filtrated with a bubble lymphoma (level 3).II. Diagnosis: Magenta cavity B-cell lymphomphomide lymphoma III, treatment in 2022-6-30, 2022-07-22, 2022-08-13, 2022-09-03, 4-course R-CHOP joint Obutini programme chemotherapy, specifically 0.7g d0, Litutau (Hanrycon), 4mgd 1, 1.3g d1 for cyclophosphoamide, 40mgd1 for polylubystar lipids, 100 mg d1-5 for pine, 150mg d1-5 for obuboneni, supported by acid, antiseptic, liver, hydrochemization, alkalinization, etc., and a smooth process of patientization. Assessment of the state of the disease, 2022.9.20 Inspection findings: 1. Post lymphoma chemotherapy review, as compared to the previous PET/CT examination (2022.06.17): an increase in lymph nodes in the third-V section of the left neck, an increase in metabolism on the left-hand collar, an increase in metabolism, a significant reduction, a decrease in metabolism, an increase in the size of the large, approximately 9*6 mm, an increase in SUVmax 1.5 (Deauville score: 2); An increase in the lymphomuth in the lymphs shown in two previous examinations, a significant decrease in the number of small lymps left lymphs in the present examination, a decrease in the number of lymphs in the present examination, and a decrease in the number of lymphs (Deauville assessment: 1; and an increase in the number of lymphatics in the third and left of the chests, a decrease in the number of lys in the present examination, and a decrease in the number of lys in theThe patient assessed the efficacy of the treatment and gave 5-8 sessions of the joint R-CHOP-Obutini programme to patients in 2022-09-25, 2022-10-16, 2022-11-8, 2022-11-29, after which the patient ‘ s 8 sessions of chemotherapy were completed in the maintenance phase, with continuous oral treatment of Obutini, and a single anti-treatment of Ottellion every February, which is being maintained until the end of the treatment and the condition is stable. Lymphoma